By a News Reporter-Staff News Editor at Gastroenterology Week -- Fresh data on Oncology are presented in a new report. According to news reporting originating from Budapest, Hungary, by NewsRx correspondents, research stated, "The effects of vitamin D3 have been investigated on various tumors, including colorectal cancer (CRC). 25-hydroxyvitamin-D3-24-hydroxylase (CYP24A1), the enzyme that inactivates the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25-D3), is considered to be the main enzyme determining the biological half-life of 1,25-D3. During colorectal carcinogenesis, the expression and concentration of CYP24A1 increases significantly, suggesting that this phenomenon could be responsible for the proposed efficacy of 1,25-D3 in the treatment of CRC."
Our news editors obtained a quote from the research from Semmelweis University, "The aim of this study was to investigate the anti-tumor effects of vitamin D3 on the human CRC cell line Caco-2 after inhibition of the cytochrome P450 component of CYP24A1 activity. We examined the expression of CYP24A1 mRNA and the effects of 1,25-D3 on the cell line Caco-2 after inhibition of CYP24A1. Cell viability and proliferation were determined by means of sulforhodamine-B staining and bromodeoxyuridine incorporation, respectively, while cytotoxicity was estimated via the lactate dehydrogenase content of the cell culture supernatant. CYP24A1 expression was measured by real-time reverse transcription polymerase chain reaction. A number of tetralone compounds were synthesized to investigate their CP24A1 inhibitory activity. In response to 1,25-D3, CYP24A1 mRNA expression was enhanced significantly, in a time-and dose-dependent manner. Caco-2 cell viability and proliferation were not influenced by the administration of 1,25-D3 alone, but were markedly reduced by co-administration of 1,25-D3 and KD-35, a CYP24A1-inhibiting tetralone. Our data suggest that the mechanism of action of co-administered KD-35 and 1,25-D3 does not involve a direct cytotoxic effect, but rather the inhibition of cell proliferation."
According to the news editors, the research concluded: "These findings demonstrate that the selective inhibition of CYP24A1 by compounds such as KD-35 may be a new approach for enhancement of the anti-tumor effect of 1,25-D3 on CRC."
For more information on this research see: CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. World Journal of Gastroenterology, 2013;19(17):2621-8. World Journal of Gastroenterology can be contacted at: W J G Press, PO Box 2345, Beijing 100023, Peoples R China. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)
The news editors report that additional information may be obtained by contacting J.P. Kosa, 1st Dept. of Internal Medicine, Semmelweis University, H-1083 Budapest, Hungary. Additional authors for this research include P. Horvath, J. Wolfling, D. Kovacs, B. Balla, P. Matyus, E. Horvath, G. Speer, I. Takacs, Z. Nagy, H. Horvath and P. Lakatos (see also Oncology).
Publisher contact information for the World Journal of Gastroenterology is: W J G Press, PO Box 2345, Beijing 100023, Peoples R China.
Keywords for this news article include: Europe, Hungary, Budapest, Oncology, Colorectal, Colon Cancer, Gastroenterology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .